Cross Medical Group Introduces HydraFacial Treatments for Advanced Skin Rejuvenation
The Philadelphia Area Team is Offering a New, Highly Customizable Skin Resurfacing Option Starting This Spring
PHILADELPHIA and VILLANOVA, Pa., May 23, 2025 (GLOBE NEWSWIRE) -- Cross Medical Group is pleased to announce that HydraFacial treatments are now available at the practice. A HydraFacial at their Philadelphia and Villanova offices, which is sometimes referred to as 'hydradermabrasion,' is an advanced skin resurfacing treatment that provides a renewed glow to your complexion through a combination of deep cleansing, exfoliation, extraction, and hydration, along with the infusion of customized serums that are designed to deeply nourish the skin. This non-invasive, medical-grade skin treatment improves many common skincare concerns with no side effects and little to no downtime.
Environmental or lifestyle factors can result in the accumulation of dead skin cells, causing your skin to appear dull, lifeless, or flaky when not removed effectively. Moreover, as your skin ages, it becomes thinner, and accumulated sun damage over the years can contribute to a loss of radiance. A HydraFacial can be ideal for removing the dead skin, debris, and oils that can build up on the outer surface of the skin. There are three main steps involved: cleansing, extraction, and hydration. In addition to removing dirt and impurities, HydraFacials also help to boost circulation.
HydraFacial patients may notice brighter and smoother skin with fewer acne breakouts after the procedure, and these results can last for up to one month or more. This gentle, highly versatile, and well-tolerated facial rejuvenation treatment is beneficial for patients of all ages, skin types, and skin tones, at any time of the year. The serums that are infused into the pores during a HydraFacial are tailored to address the specific needs of each patient. They provide plumper, deeply hydrated, and nourished skin.
Cross Medical Group also offers many surgical cosmetic treatments for the face, breast, and body, along with other non-surgical treatments including minimally invasive injectables, skin rejuvenation and resurfacing options, lasers and lights, and body contouring procedures at their offices in Philadelphia and Villanova. Their team is committed to the utmost safety and high-quality results.
For more information about HydraFacials, contact Cross Medical Group. Call their office in Philadelphia (215) 561-9100 or Main Line's Villanova (610) 688-9100. You can also send a message online to request a consultation.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support
National Platform Offers Secure Access to Physician-Led TRT and Hormone Health Consultations from Anywhere in the U.S. VERO BEACH, June 10, 2025 (GLOBE NEWSWIRE) -- PeterMD, a Florida-based men's health telemedicine provider, has updated its official website to spotlight its nationwide services focused on testosterone replacement therapy (TRT), hormone optimization, and performance support. Available in all 50 states, PeterMD offers direct-to-consumer access to licensed providers via a secure digital platform. According to the official website ( PeterMD allows adult men to privately consult with certified TRT specialists, receive personalized treatment plans based on lab results, and manage therapy from the comfort of home. Services are available without insurance requirements, with fast turnaround times and HIPAA-compliant care. 'PeterMD was built to eliminate unnecessary barriers to men's health,' said a company spokesperson. 'We believe in transparent, physician-directed care that gives men control over their wellness without waiting rooms or stigma.' The telemedicine platform includes options for lab testing coordination, treatment supervision, and ongoing patient support. Every consultation is handled by a qualified medical professional trained in men's hormone health. Once a plan is approved, therapies are shipped directly with complete oversight from the PeterMD medical team. The updated site features secure registration, FAQs, and real-time access to specialists. New clients are invited to speak directly with a TRT specialist by calling or texting 772-800-6133. For existing patients, dedicated support is available at 772-444-8669 or via email at support@ PeterMD patient support hours: Monday–Sunday: 7 AM – 7 PM EST (for new inquiries) Monday–Friday: 9 AM – 5 PM EST (for existing patients) About PeterMD PeterMD is a telehealth provider based in Vero Beach, Florida, offering customized men's hormone and wellness solutions across the United States. The platform connects users with medical experts for private, fast, and clinically guided treatment—empowering men to reclaim their energy, focus, and vitality through modern, accessible care. Product and Contact Information Brand: PeterMDWebsite: support@ (New Patients): 772-800-6133Phone (Support): 772-444-8669Mailing Address: 601 21st Street, Suite 300, Vero Beach, FL, United StatesBusiness Hours:New Patients: Monday–Sunday, 7 AM – 7 PM ESTSupport: Monday–Friday, 9 AM – 5 PM EST Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All medical decisions should be made in consultation with a licensed healthcare provider. Availability of telemedicine services may vary by state. PeterMD complies with all applicable healthcare regulations. CONTACT: Email: support@ Phone (New Patients): 772-800-6133 Phone (Support): 772-444-8669Sign in to access your portfolio
Yahoo
37 minutes ago
- Yahoo
The Memory Breath Releases Latest Customer Reviews Using This Daily Breathing Ritual
Website Update Showcases Affordable Digital Ritual for Focus and Mental Clarity Without Pills or Supplements New York, June 10, 2025 (GLOBE NEWSWIRE) -- The Memory Breath, a digital wellness brand focused on natural brain support, has updated its official website to showcase the latest customer feedback surrounding its daily breathing ritual audio. Designed to support calm clarity and cognitive balance, the non-pill format is now accessible online as an easy-to-use digital experience. According to the official website ( The Memory Breath is not a supplement, but a guided digital audio sequence developed to align with the body's natural neurological rhythms. The brand positions its routine as an accessible, affordable alternative to high-priced cognitive supplements—without the need for capsules, additives, or restrictive programs. 'The simplicity of this ritual is what sets it apart—it's sound-based, soothing, and rooted in the body's natural patterns,' said a company spokesperson. 'We're committed to making natural brain support accessible without relying on unproven pills.' The company notes that this audio-guided approach is intended to help activate a neurological pathway referred to as 'BNO,' linked to focus, memory, and mental clarity. According to internal testing, the ritual may support up to 20x greater engagement with this pathway compared to certain popular supplements, although individual results may vary. Recent updates to the website include new customer insights, simplified access to the program, and an overview of the intended wellness applications of the audio routine. The Memory Breath includes a satisfaction guarantee and direct support for first-time users. About The Memory Breath The Memory Breath is a digital-first wellness brand offering audio-based rituals designed to support focus, mental clarity, and natural cognitive balance. Rooted in simplicity and sound science, the brand avoids pills and embraces accessible, non-invasive approaches to everyday wellness. Product and Contact Information Brand: The Memory BreathWebsite: support@ Service: 1-800-390-6035 Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new wellness routine. CONTACT: Email: support@ Customer Service: 1-800-390-6035Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE: BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders. As part of the collaboration, Bexorg's novel whole-brain discovery platform will be used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven. Bexorg's whole-brain discovery platform is the only technology capable of perfusing isolated, cadaver human and pig brains with custom-made artificial blood, thereby restoring metabolic and molecular activity for prolonged periods. Bexorg's founders developed the whole-brain perfusion technology at Yale University. Using it, the company can extract high-resolution transcriptomic, proteomic, and metabolic insights in disease-relevant states. With this information, Bexorg is building the largest and most physiologically relevant datasets in human neurodegeneration to enable machine learning and artificial intelligence (AI)-centered CNS drug discovery and development. This breakthrough aims to provide unparalleled insights into human brain molecular activity and advances in the understanding of CNS disorders. 'Our technology enables preclinical testing of almost any therapeutic in metabolically active whole human brains, whether diseased or non-diseased, providing a significant advantage over any other preclinical model in neuroscience,' said Zvonimir Vrselja, MD, PhD, CEO and Co-founder at Bexorg. 'Our ability to collect longitudinal data from our whole-brain discovery platform allows us to validate new targets and biomarkers and understand the pharmacokinetic and pharmacodynamic profiles and potential safety and effectiveness of drugs before going into the clinic. We are thrilled to team up with Biohaven to help advance two preclinical programs and potentially unlock a faster, more precise path to new CNS therapies.' 'The lack of robust translational preclinical models that adequately capture the complexity of human brain structure and function, including the architecture and dynamics of neural networks comprised of billions of neurons and glial cells and the trillions of connections that exist between them, and account for physiological gradients of drug exposure throughout the brain associated with distinct profiles of drug transport across the blood-brain barrier, has, until now, severely handicapped CNS drug discovery and development,' said Bruce D. Car, DVM, PhD, DACVP, Chief Scientific Officer at Biohaven. 'Bexorg's novel platform effectively overcomes the myriad deficiencies inherent in this translational gap, permitting unprecedented and detailed insights into the CNS pharmacology, dosimetry, and potential efficacy of drug candidates before advancing to costly and time-consuming clinical trials.' As part of the collaboration, Bexorg aims to deliver insights from systemic delivery of Biohaven's therapeutics, including analysis of pharmacokinetics, pharmacodynamics, and mechanism of action. Data generated from the platform may also potentially point to the responsiveness of patient subpopulations and identify novel biomarkers to inform clinical trials. Financial terms of the collaboration were not disclosed. About BiohavenBiohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and nonclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visit About BexorgBexorg is a privately held techbio company with the first-ever full-stack tech platform to support central nervous system (CNS) drug discovery and development in the human brain in a way that has not been possible before. Bexorg is building a drug discovery artificial intelligence (AI) loop based on its proprietary wet-lab platform, BrainEx, which enables restoration of molecular activity in postmortem human brains to generate high-fidelity, clinically predictive data, model drug response, and create a foundation model for CNS discovery. The company is generating large volumes of human brain data to train predictive models across diseases. Bexorg is building an AI engine, XO Digital, which learns from each experiment, creating a closed-loop system of in-silico prediction and wet-lab validation. With this fully integrated platform, Bexorg is setting a new standard for CNS translational and discovery research. In collaboration with the National Institutes of Health (NIH), Bexorg's founders have been at the forefront of bioethics in postmortem brain molecular recovery research, and the company has an independent board comprised of bioethics leaders to ensure its operations maintain the highest standards. Bexorg is strategically partnering with leading neuroscience companies to integrate its platform into clinical development programs, as well as advancing in-house neurodegeneration assets. Visit us at and follow us on LinkedIn to learn more. Biohaven's Forward-looking StatementsThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'next generation', 'most', 'unparalleled', 'largest', significant', 'novel', 'unprecedented', and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. CONTACT: Bexorg Media Contact: Adam Silverstein SCIENT PR adam@ Biohaven Contacts: Investor Contact: Jennifer Porcelli Vice President, Investor Relations +1 (201) 248-0741 Media Contact: Mike Beyer Sam Brown Inc. mikebeyer@ +1 (312) 961-2502
